CODX earnings: next report 2026-08-14, real EPS beat/miss history, analyst consensus Hold, P/E -0.07. Updated 2026-07-23.
Co-Diagnostics (CODX) Research Hub
Co-Diagnostics (CODX) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-09-11, shares last closed at 1.12 USD (0.00%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -0.07, market cap 0.00B. This hub links to the full technical, earnings and options research available for CODX.
Last updated 2026-09-11 · Source: FMP end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 1.12 USD (0.00%) |
| 52-week range | 0.94 USD – 4.17 USD |
| Trend regime | Range |
| 14-day RSI | 21.4 (Oversold) |
| Trailing P/E | -0.07 |
| Market cap | 0.00B |
| Dividend yield | 0.00% |
| Next earnings | 2026-08-14 |
Available research for CODX
Covered Call on CODX: how it works, illustrative setup around the real 1.12 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on CODX: how it works, illustrative setup around the real 1.12 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on CODX: how it works, illustrative setup around the real 1.12 USD price, max profit/loss, breakeven and when to use it. Educational.
CODX technical analysis: range, last 1.12 USD, RSI 21.4, 52w range 0.94 USD–4.17 USD, real support/resistance. Updated 2026-09-11.
Frequently asked questions
What sector is CODX in?
Co-Diagnostics (CODX) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.
Is CODX in an uptrend or downtrend?
As of 2026-09-11, CODX is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is CODX's trailing P/E ratio?
CODX's trailing P/E is -0.07, with a market cap of 0.00B. See the earnings research page for full valuation detail.
When does CODX next report earnings?
CODX is next scheduled to report earnings on 2026-08-14, with a consensus EPS estimate of -3 USD.